{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-004481","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.430951+00:00","generated_at":"2026-06-19T15:59:21.534173+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Processa Pharmaceuticals raises $6.25M in registered direct offering at $0.80/share","bullets":["Sold 7,812,544 shares at $0.80/share; gross proceeds $6.25M, net ~$5.7M after fees.","Closing expected Feb 14, 2023; Spartan Capital acted as sole placement agent.","Proceeds to fund clinical trials, R&D, working capital, and general corporate purposes.","Issuer subject to 90-day lockup until stock exceeds $2.00 for 10 consecutive trading days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-004481","json":"https://secwatch.observer/filing/0001493152-23-004481.json","markdown":"https://secwatch.observer/filing/0001493152-23-004481.md","text":"https://secwatch.observer/filing/0001493152-23-004481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223004481/0001493152-23-004481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223004481/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T15:59:21.534173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3343c1aeecf85320dfe6dee5cf2d47d340c948ae","claim":"Processa Pharmaceuticals, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $6.25 million (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, Processa Pharmaceuticals, Inc. (the “Company”) and certain accredited investors (the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) relating to the issuance and sale of shares of common stock pursuant to a registered direct offering (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223004481/0001493152-23-004481-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $6.25 million"},{"label":"Effective","value":"2023-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}